• Fourth quarter revenue of $16.8 million increased 42% on a constant currency basis compared to prior year period
• 2015 revenue of $62.8 million increased 33% on a constant currency basis compared to prior year
• T-SPOT®.PRT assay made available in the United States as laboratory developed test (LDT) • Gained CE Mark for the T-SPOT.PRT assay
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 1, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced fourth quarter and full year 2015 financial results.
“We are pleased with our fourth quarter financial and operating results as well as the significant progress we made during 2015,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “Our sales performance, driven by accelerated growth in all geographies, exceeded expectations. We are also excited by the progress we made in our pipeline during the year and look forward to the many growth opportunities for our business in the future.”
For full access, please click here.
